<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03079557</url>
  </required_header>
  <id_info>
    <org_study_id>ESA 17/1878</org_study_id>
    <secondary_id>2016-000326-19</secondary_id>
    <nct_id>NCT03079557</nct_id>
  </id_info>
  <brief_title>Feasibility Pilot for the ReBOO-trial</brief_title>
  <acronym>ReBOO</acronym>
  <official_title>A Non-randomised, Open Feasibility Pilot for the 'REpurposing BOtulinum Toxin in Treatment of Obesity in Adolescents' (ReBOO) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Olavs Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot testing the feasibility of the 'REpurposing BOtulinum Toxin in Treatment of
      Obesity in Adolescents' trial (ReBOO-trial). The full-scale ReBOO will further investigate
      safety and efficacy of intragastric injections of botulinum toxin A into the antrum area of
      the stomach. These injections will be repeated every six months.

      The study sample will be adolescents with obesity who have not responded to standard
      conservative treatment.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 14, 2017</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BMI</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of participants reaching a reduction in BMI z-score equal to or more than 1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Injection interval</measure>
    <time_frame>12 months</time_frame>
    <description>Patient reports will indicate the appropriate re-injection interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient adherence to treatment</measure>
    <time_frame>12 months</time_frame>
    <description>Qualitative data based on interviews with patients and next of kin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>All adverse events (AE), serious adverse events (SAE) and suspected unexpected serious adverse reactions (SUSAR) will be evaluated</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Intragastric botulinum toxin type A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Botulinum toxin A (Allergan) injected intragastrically in the antrum</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intragastric botulinum toxin type A</intervention_name>
    <description>200 units Botulinum toxin A (Allergan) injected intragastrically in the antrum every six months</description>
    <arm_group_label>Intragastric botulinum toxin type A</arm_group_label>
    <other_name>Allergan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written (signed) informed consent

          2. Age and gender adjusted body mass index (ISO-BMI) â‰¥ 35 or ISO-BMI &gt; 30 with
             comorbidities including hypertension, non-alcoholic fatty liver disease,
             hyperlipidemia or impaired glucose tolerance

          3. Having partaken in a comprehensive multi-disciplinary lifestyle treatment for obesity
             of duration 12 months or more, without achieving a clinically significant weight loss
             (non-responder)

        Exclusion Criteria:

          1. Known hypersensitivity to excipients in the investigational medicine product (IMP)

          2. Neuromuscular disorders

          3. History of dysphagia

          4. History of aspiration tendency or aspiration pneumonia

          5. Known lung disease under continuous treatment

          6. Congenital or acquired heart disease

          7. Previous experience of side effects to Botulinum toxin type A

          8. Present gastric diseases or dysfunction

          9. Previous bariatric surgery

         10. History of cancer

         11. Serious binge eating disorder

         12. Untreated hypothyroidism

         13. Use of aminoglycoside antibiotics or spectinomycin in the week prior to injection, or
             any other medicinal product that interfere with neuromuscular transmission
             (neuromuscular blocking agents)

         14. Medication known to affect appetite

         15. Syndromic obesity

         16. Mentally immature to a degree that there is doubt about the subject's ability to
             assent

         17. Issues relating to language or culture that may complicate trial participation

         18. Pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Petter Aadahl, md prof</last_name>
    <role>Study Director</role>
    <affiliation>St. Olavs Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Olavs Hospital Trondheim University Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2017</study_first_submitted>
  <study_first_submitted_qc>March 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2017</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adolescent</keyword>
  <keyword>Injections, intraperitoneal</keyword>
  <keyword>Endoscopy</keyword>
  <keyword>Botulinum Toxins, Type A</keyword>
  <keyword>OnabotulinumtoxinA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

